This study is accepting new patients by invitation only

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

a study on Duchenne Muscular Dystrophy

Summary

Eligibility
for males (full criteria)
Location
at UC Davis UCLA
Dates
study started
study ends around

Description

Summary

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

Official Title

A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study

Keywords

Duchenne Muscular Dystrophy, DMD, Pediatric, Long-term, Follow-up, Safety, Efficacy, delandistrogene moxeparvovec

Eligibility

You can join if…

Open to males

  • Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study.
  • Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.

You CAN'T join if...

  • Not applicable

Locations

  • UCLA Medical Center
    Los Angeles California 90095 United States
  • University of California, Davis
    Sacramento California 95817 United States
  • Rady Children's Hospital
    San Diego California 92123 United States
  • Lucile Packard Children's Hospital Stanford (LPCH)
    Palo Alto California 94304 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Sarepta Therapeutics, Inc.
ID
NCT05967351
Phase
Phase 3 Duchenne Muscular Dystrophy Research Study
Study Type
Interventional
Participants
Expecting 400 study participants
Last Updated